424 completed, 130 terminated, 56 active not recruiting, 47 unknown. 454 Phase 2, 239 Phase 1, 101 Phase 3, 11 Not applicable, 7 Early Phase 1.
Follow Gemzar: new trials by email Literature Review of Gemzar trials Research Report on Gemzar
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors Olaparib, Gemcitabine, Docetaxel - Germ Cell Cancer | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 36 | 2027-03-01 | 2026-10-01 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma Tremelimumab, Durvalumab, Gemcitabine - Combined Hepatocellular and Cholangiocarcinoma | Phase 2 | Not yet recruiting | Mehmet Akce | 29 | 2026-11-01 | 2026-11-04 |
| Bladder Preservation or Cystectomy for MIBC Gemzar, Cisplatin, Adrucil - Muscle-Invasive Bladder Carcinoma, Bladder Cancer | Early Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 20 | 2026-09-02 | 2026-09-15 |
| ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine - Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Michael Spinner, MD | 38 | 2026-08-18 | 2026-10-20 |
| Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms Ablation Therapy, Biospecimen Collection, Computed Tomography - Pancreatic Cystic Neoplasm | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 35 | 2026-05-12 | 2026-05-29 |
| Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma Cemiplimab Plus Gemcitabine - Pancreatic Ductal Adenocarcinoma (mPDAC) | Phase 2 | Recruiting | University of California, San Diego | 43 | 2026-05-06 | 2026-06-08 |
| Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer Emavusertib, Gemcitabine, Cisplatin - Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma | Phase 1 | Recruiting | Washington University School of Medicine | 48 | 2026-03-27 | 2026-04-03 |
| ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma ONT01, Gemcitabine, Nab paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 61 | 2026-03-25 | 2026-05-19 |
| A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients Ascorbate, Gemcitabine, radiation therapy - Pancreatic Neoplasm | Phase 2 | Withdrawn | Joseph J. Cullen, MD, FACS | 2025-12-31 | 2025-03-10 | |
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer Evorpacept (ALX148), Trastuzumab, Paclitaxel - Breast Cancer, Metastatic | Phase 2 | Recruiting | ALX Oncology Inc. | 120 | 2025-12-10 | 2026-09-25 |
| A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel - Carcinoma, Non-Small -Cell Lung | Phase 3 | Recruiting | Maia Biotechnology | 300 | 2025-12-08 | 2026-01-12 |
| Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer N-803 and BCG, N-803 and Gemcitabine - Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 20 | 2025-11-01 | 2025-10-16 |
| A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors ERAS-0015, ERAS-0015 in combination - Metastatic Solid Tumors | Phase 1 | Recruiting | Erasca, Inc. | 600 | 2025-06-05 | 2026-11-06 |
| A Study of PHST001 in Advanced Solid Tumors PHST001, Paclitaxel, Topotecan - Advanced Solid Tumors, Ovarian Cancer | Phase 1 | Recruiting | Pheast Therapeutics | 426 | 2025-03-31 | 2026-10-05 |
| Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer sintilimab, nab-paclitaxel, gemcitabine - Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 50 | 2025-03-20 | 2025-01-22 |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication - Triple Negative Breast Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1000 | 2025-03-16 | 2026-10-13 |
| Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer Nab paclitaxel, Gemcitabine, TheraBionic P1 - Metastatic Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Barbara Ann Karmanos Cancer Institute | 30 | 2025-02-28 | 2026-08-10 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
Showing 20 of 726. Sign in to see all of them.
Pancreatic Neoplasms (257) · Carcinoma, Non-Small-Cell Lung (75) · Neoplasms (65) · Breast Neoplasms (57) · Neoplasm Metastasis (46) · Lung Neoplasms (39) · Urinary Bladder Neoplasms (33) · Ovarian Neoplasms (31) · Cholangiocarcinoma (26) · Gallbladder Neoplasms (23) · Hodgkin Disease (23) · Sarcoma (23) · Fallopian Tube Neoplasms (21) · Lymphoma (21) · Adenocarcinoma (19)
National Cancer Institute (NCI) (77) · M.D. Anderson Cancer Center (41) · Eli Lilly and Company (36) · Mayo Clinic (14) · Washington University School of Medicine (13) · SCRI Development Innovations, LLC (12) · Hellenic Oncology Research Group (10) · Celgene (9) · SWOG Cancer Research Network (9) · Columbia University (8) · H. Lee Moffitt Cancer Center and Research Institute (8) · Dana-Farber Cancer Institute (7) · ECOG-ACRIN Cancer Research Group (7) · Merck Sharp & Dohme LLC (7) · Stanford University (7)
United States (523) · Spain (61) · Canada (54) · France (51) · Italy (50) · China (48) · Germany (47) · Belgium (41) · United Kingdom (41) · South Korea (38) · Australia (34) · Taiwan (28) · Greece (25) · Japan (24) · Poland (24)
Yago Nieto, MD, PHD (6) · Hedy Kindler (5) · Michele Reni, MD (5) · Vassilis Georgoulias, MD (5) · Albert Koong (3) · Alex Adjei (3) · Armando Santoro, MD (3) · Benjamin Tan, M.D. (3) · David R. Spigel, MD (3) · Denise A. Yardley, MD (3)
PMID 31401903, PMID 37185961, PMID 29929491, PMID 33951890, PMID 42176183, PMID 15297403, PMID 16277889, PMID 17329192, PMID 17909804, PMID 18650621, PMID 19087987, PMID 19224841, PMID 19415121, PMID 19560257, PMID 19636002, PMID 19661042, PMID 19819914, PMID 19932054, PMID 20163987, PMID 20164695, PMID 20375404, PMID 20421819, PMID 20439197, PMID 20461379, PMID 20497920, PMID 20585851, PMID 20662793, PMID 20863157, PMID 20881641, PMID 20981545, PMID 21120580, PMID 21135251, PMID 21444871, PMID 21595953, PMID 21783417, PMID 21833720, PMID 22080439, PMID 22094934, PMID 22124104, PMID 22162229, PMID 22218909, PMID 22266043, PMID 22285168, PMID 22338014, PMID 22634531, PMID 22736441, PMID 22775314, PMID 23229886, PMID 23275061, PMID 23381814
U10CA180820 (12), P30CA015083 (9), U10CA021115 (7), U10CA027469 (7), U10CA032102 (7), U10CA180868 (7), P30CA036727 (6), 2023 (5), U10CA021661 (5), U10CA031946 (5), U10CA180821 (5), U10CA180888 (5), 2016 (4), N01CM00038 (4), N01CM62204 (4)